• Cellectis highlighted progress on lasme-cel, now in a pivotal Phase 2 study in relapsed or refractory B‑cell acute lymphoblastic leukemia.
• Full Phase 1 results were presented at the 2026 European Hematology Association meeting, supporting continued development based on encouraging responses and manageable safety.
• An interim readout from the pivotal Phase 2 study is scheduled for Q4 2026, a key catalyst for regulatory strategy.
• The company also advanced eti-cel in an ongoing Phase 1 study in relapsed or refractory B‑cell non‑Hodgkin lymphoma.
• Translational findings were presented at EHA 2026; the full Phase 1 clinical dataset is expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.